` VERV (Verve Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

VERV
vs
S&P 500

Over the past 12 months, VERV has underperformed S&P 500, delivering a return of -6% compared to the S&P 500's 8% growth.

Stocks Performance
VERV vs S&P 500

Loading
VERV
S&P 500
Add Stock

Performance Gap
VERV vs S&P 500

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
VERV vs S&P 500

Loading
VERV
S&P 500
Add Stock

Competitors Performance
Verve Therapeutics Inc vs Peers

S&P 500
VERV
ABBV
AMGN
GILD
VRTX
Add Stock

Verve Therapeutics Inc
Glance View

Market Cap
513m USD
Industry
Biotechnology

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. The company is headquartered in Cambridge, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2021-06-17. The firm is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The company is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The firm's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The firm's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

VERV Intrinsic Value
HIDDEN
Show
Back to Top